- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: May 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in May 2027, from ClinicalTrials.gov.
Trial readouts
190 trials: 77 phase 3 (including phase 2/3) and 113 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| May 2027 | AbbVie | UbrogepantStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescen… | Migraine | Phase 3 | Recruiting | NCT05125302 |
| May 2027 | Aerogen Pharma Limited | APC-0101 (SF-RI 1 surfactant for inhalation combined with …, ControlSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | Respiratory Distress Syndrome, Pre-term Infants | Phase 3 | Recruiting | NCT06776783 |
| May 2027 | Akeso | Ivonescimab, docetaxelIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Phase 3 | Recruiting | NCT06928389 |
| May 2027 | Alkermes | ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | Narcolepsy Type 2 | Phase 3 | Recruiting | NCT07502443 |
| May 2027 | Alkermes | ALKS 2680 Dose 1, ALKS 2680 Dose 2A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | Narcolepsy Type 1 | Phase 3 | Recruiting | NCT07455383 |
| May 2027 | Barbara Maglione | CLR Tablets - Heparan SulphateRandomized, Placebo-crontrolled Clinical Trial Evaluating the Efficacy and Safety of Heparan Sulfate 120 mg Prolonged-Release Tablets Compar… | Chronic Venous Disease, Vein Disease and 1 more | Phase 3 | Not yet recruiting | NCT07684833 |
| May 2027 | Beijing Kanghong Biological Medicine Co., Ltd. | KHN939A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease | Thyroid Eye Disease | Phase 3 | Not yet recruiting | NCT07720648 |
| May 2027 | Bigespas LTD | DMB-I (INN: Latrepirdine), Memantine Hydrochloride 20 MGEfficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia | Alzheimer Type Dementia | Phase 3 | Recruiting | NCT07251023 |
| May 2027 | Crinetics Pharmaceuticals | AtumelnantA Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 3 | Recruiting | NCT07144163 |
| May 2027 | Eli Lilly and Company | OrforglipronA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | Diabetes Mellitus, Type 2, Diabetes Melletus and 14 more | Phase 3 | Recruiting | NCT07613307 |
| May 2027 | Eli Lilly and Company | LY3650150, Standard therapy for INCSA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO… | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 3 | Recruiting | NCT06338995 |
| May 2027 | GRIN Therapeutics, Inc. | RadiprodilBeeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | GRIN-related Neurodevelopmental Disorder | Phase 3 | Recruiting | NCT07224581 |
| May 2027 | Gameto, Inc. | Fertilo, Medicult IVMFertilo In Vitro Research Study and Trial | In Vitro Maturation of Oocytes | Phase 3 | Recruiting | NCT06858111 |
| May 2027 | Genetix Biotherapeutics Inc. | bb1111A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease | Sickle Cell Disease | Phase 3 | Active not recruiting | NCT04293185 |
| May 2027 | Huons Biopharma | HU-045, Xeomin®To Evaluate HU-045 With Moderate to Severe Glabellar Lines | Glabellar Lines | Phase 3 | Recruiting | NCT07870694 |
| May 2027 | Jiangsu Hengrui Medicine | SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection and 2 moreA Study of SHR-A1811 in Subjects With Ovarian Cancer | Ovarian Cancer | Phase 3 | Recruiting | NCT06828354 |
| May 2027 | Minoryx Therapeutics, S.L. | LeriglitazoneA Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy | Cerebral Adrenoleukodystrophy (cALD) | Phase 3 | Active not recruiting | NCT05819866 |
| May 2027 | Viatris | Transdermal system containing progestinStudy to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential | Female Contraception | Phase 3 | Active not recruiting | NCT06672016 |
| May 2027 | OKYO Pharma Ltd | Urcosimod ophthalmic solution is a preservative-free topic…Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solutio… | Neuropathic Corneal Pain | Phase 3 | Not yet recruiting | NCT07838506 |
| May 2027 | Priothera SAS | mocravimodMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Adult Acute Myeloid Leukemia | Phase 3 | Recruiting | NCT05429632 |
| May 2027 | Qilu Pharmaceutical Co., Ltd. | QLG2128, Teriparatide InjectionTo Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at H… | Postmenopausal Women With Osteoporosis | Phase 3 | Not yet recruiting | NCT06898060 |
| May 2027 | Qilu Pharmaceutical Co., Ltd. | QL2108 injection, Dupixent®A Phase Ⅲ Comparative Study of QL2108 to Dupixent® | Atopic Dermatitis | Phase 3 | Not yet recruiting | NCT06884891 |
| May 2027 | Qilu Pharmaceutical Co., Ltd. | Daprodustat, Darbepoetin alfaA Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With … | Anaemia | Phase 3 | Not yet recruiting | NCT07300111 |
| May 2027 | Qilu Pharmaceutical Co., Ltd. | MHB088C for Injection, Topotecan, Irinotecan and 1 moreA Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Small Cell Lung Cancer Extensive Stage | Phase 3 | Recruiting | NCT06954246 |
| May 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumi…A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer | HER2-low Breast Cancer | Phase 3 | Recruiting | NCT06957886 |
| May 2027 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | SKB264, OsimertinibA Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Loc… | Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | NCT06670196 |
| May 2027 | Skyhawk Therapeutics, Inc. | SKY-0515Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease | Huntington Disease, Huntingtons Disease | Phase 2/3 | Active not recruiting | NCT06873334 |
| May 2027 | Sun Pharmaceutical | CTP-543Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | Alopecia Areata | Phase 2/3 | Active not recruiting | NCT03898479 |
| May 2027 | Verrica Pharmaceuticals Inc. | VP-102 (US) / TO-208 (Japan)Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) | Common Warts, Common Warts (Verruca Vulgaris) and 2 more | Phase 3 | Recruiting | NCT07637734 |
| May 2027 | Xenon Pharmaceuticals | AzetukalnerA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Major Depressive Disorder | Phase 3 | Active not recruiting | NCT07076407 |
| May 1, 2027 | IntraBio Inc | N-Acetyl-L-LeucinePivotal Study of N-acetyl-L-leucine for CACNA1A | CACNA1A, Spinocerebellar Ataxia Type 6 and 2 more | Phase 3 | Recruiting | NCT07221292 |
| May 2, 2027 | Pfizer | AbrocitinibA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema | Eczema | Phase 3 | Recruiting | NCT06807268 |
| May 4, 2027 | Amgen | Romosozumab, BisphosphonateStudy to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta | Osteogenesis Imperfecta | Phase 3 | Active not recruiting | NCT05972551 |
| May 5, 2027 | Merck & Co. | Pembrolizumab, Olaparib, Etoposide and 6 moreStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell… | Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | NCT04380636 |
| May 6, 2027 | Sanofi | Frexalimab, Teriflunomide, MRI contrast-enhancing agents and 2 moreEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Phase 3 | Active not recruiting | NCT06141473 |
| May 6, 2027 | UCB | RozanolixizumabA Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody… | Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) | Phase 3 | Active not recruiting | NCT05063162 |
| May 7, 2027 | Innovent Biologics | IBI362A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | Sleep Apnea, Obstructive and 1 more | Phase 3 | Recruiting | NCT06931028 |
| May 10, 2027 | Merck & Co. | Sacituzumab tirumotecan, Docetaxel, PemetrexedSacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (N… | Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Active not recruiting | NCT06074588 |
| May 10, 2027 | Novartis | Inclisiran sodium 300 mgStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Atherosclerotic Cardiovascular Disease | Phase 3 | Active not recruiting | NCT05030428 |
| May 11, 2027 | Roche Holding | Baloxavir MarboxilA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to House… | Influenza | Phase 3 | Recruiting | NCT06094010 |
| May 11, 2027 | Novo | CagrilintideWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | Obesity, Overweight | Phase 3 | Active not recruiting | NCT07220642 |
| May 12, 2027 | Novo | CagrilintideWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | Overweight, Obesity and 1 more | Phase 3 | Active not recruiting | NCT07220759 |
| May 12, 2027 | RemeGen Co., Ltd. | RC148 (Dose 1) plus Capecitabine and Oxaliplatin, RC148 (Dose 2) plus Capecitabine and OxaliplatinA Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | Colorectal (Colon or Rectal) Cancer | Phase 2/3 | Recruiting | NCT07462143 |
| May 14, 2027 | Akeso | Ivonescimab, AK117, Albumin-bound Paclitaxel, GemcitabineA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | Pancreatic Cancer | Phase 3 | Recruiting | NCT06953999 |
| May 14, 2027 | GSK | Tafenoquine, Primaquine, ChloroquineAn Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chlor… | Malaria, Vivax | Phase 3 | Recruiting | NCT06666491 |
| May 14, 2027 | Johnson & Johnson | NipocalimabEfficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 2/3 | Recruiting | NCT05327114 |
| May 15, 2027 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1802 injectionA Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. | Allergic Rhinitis, Seasonal | Phase 3 | Not yet recruiting | NCT07199257 |
| May 16, 2027 | Pfizer | RSVpreFA Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults | Adult, Healthy Participants | Phase 3 | Recruiting | NCT07819097 |
| May 17, 2027 | Novartis | Remibrutinib Dose A, Remibrutinib Dose BA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidraden… | Hidradenitis Suppurativa | Phase 3 | Active not recruiting | NCT06799000 |
| May 17, 2027 | Paradigm Therapeutics | SD-101 Dermal Cream (6%)Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | Epidermolysis Bullosa (EB) | Phase 3 | Recruiting | NCT07482787 |
| May 17, 2027 | Regeneron Pharmaceuticals | REGN7508, Acetylsalicylic Acid (ASA)REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | Symptomatic Venous Thromboembolism (VTE) | Phase 3 | Recruiting | NCT07213778 |
| May 17, 2027 | Sanofi | PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine and 4 moreStudy of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | Pneumococcal Immunization | Phase 3 | Active not recruiting | NCT06736041 |
| May 18, 2027 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 10mg QY201 tablet, 20mg QY201 tabletA Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis. | Atopic Dermatitis (AD) | Phase 3 | Enrolling by invitation | NCT07180511 |
| May 18, 2027 | Novo | CagrilintideA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Overweight, Obesity | Phase 3 | Recruiting | NCT07745504 |
| May 18, 2027 | Takeda Pharmaceutical Company | ZasocitinibA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | Psoriatic Arthritis | Phase 3 | Active not recruiting | NCT06671496 |
| May 18, 2027 | Takeda Pharmaceutical Company | Zasocitinib, Active ComparatorA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Psoriatic Arthritis | Phase 3 | Recruiting | NCT06671483 |
| May 19, 2027 | Merck & Co. | Nemtabrutinib, Fludarabine, Cyclophosphamide and 5 moreA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lym… | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | NCT05624554 |
| May 20, 2027 | Biogen | BIIB017 (peginterferon beta-1a), Interferon beta type 1aA Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of… | Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Active not recruiting | NCT03958877 |
| May 27, 2027 | Merck & Co. | pembrolizumab, carboplatin, paclitaxel and 2 moreStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-347… | Endometrial Neoplasms | Phase 3 | Active not recruiting | NCT05173987 |
| May 27, 2027 | Otsuka Pharmaceutical | Centanafadine XRA Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation | Phase 3 | Recruiting | NCT07759154 |
| May 27, 2027 | Taiho Oncology, Inc. | TAS6417REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | Phase 3 | Active not recruiting | NCT05973773 |
| May 28, 2027 | AstraZeneca | DanicopanStudy of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extra… | Paroxysmal Nocturnal Hemoglobinuria, PNH and 1 more | Phase 3 | Recruiting | NCT06449001 |
| May 28, 2027 | AstraZeneca | laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3 and 5 moreA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholestero… | Hypercholesterolaemia | Phase 3 | Recruiting | NCT07619118 |
| May 28, 2027 | Otsuka Pharmaceutical | BPaQM, BPaLM, BPaQ and 1 moreA Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis | Pulmonary Tuberculosis | Phase 3 | Recruiting | NCT07209761 |
| May 29, 2027 | Beijing QL Biopharmaceutical Co.,Ltd | Zovaglutide dose 1, Zovaglutide dose 2A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1) | Overweight , Obesity | Phase 3 | Active not recruiting | NCT07230119 |
| May 30, 2027 | Qilu Pharmaceutical Co., Ltd. | Meropenem and Pralurbactam, Ceftazidime-avibactam, MetronidazoleStudy to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI | Intra-abdominal Infections | Phase 3 | Not yet recruiting | NCT06633718 |
| May 30, 2027 | Shanghai Xinzhi BioMed Co., Ltd. | Single dose intravenous injection of BBM-H803Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs | Hemophilia A | Phase 2/3 | Recruiting | NCT06111638 |
| May 30, 2027 | Takeda Pharmaceutical Company | ZasocitinibA Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis | Palmoplantar Psoriasis | Phase 3 | Not yet recruiting | NCT07752108 |
| May 31, 2027 | Annexon, Inc. | TanruprubartAn Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD … | Guillain-Barre Syndrome | Phase 3 | Recruiting | NCT07020819 |
| May 31, 2027 | Biogen | FelzartamabA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | NCT06935357 |
| May 31, 2027 | Evopoint Biosciences Inc. | XNW28012 for injection, XNW28012 Mimetic for InjectionStudy of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy | Pancreatic Cancer | Phase 3 | Recruiting | NCT07823049 |
| May 31, 2027 | Sarepta Therapeutics | delandistrogene moxeparvovecA Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulator… | Duchenne Muscular Dystrophy | Phase 3 | Active not recruiting | NCT05881408 |
| May 31, 2027 | Shanghai JMT-Bio Inc. | JMT103, zoledronic acidA Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Com… | Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors | Phase 3 | Not yet recruiting | NCT06221072 |
| May 31, 2027 | Suzhou Immunofoco Biotechnology Co., Ltd | CAR T cells, ControlA Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients | Gastric Adenocarcinoma | Phase 3 | Recruiting | NCT07103668 |
| May 31, 2027 | Taisho Pharmaceutical Co., Ltd. | 'TS-172 20~60 mg/dayA Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis | Hyperphosphatemia Patients on Peritoneal Dialysis | Phase 3 | Recruiting | NCT07548853 |
| May 31, 2027 | Tasly Pharmaceutical Group Co., Ltd | Susu Xiao'er Zhike Granules, Extremely-low dose Susu Xiao'er Zhike GranulesPhase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment | Cough | Phase 3 | Not yet recruiting | NCT06773117 |
| May 31, 2027 | Vertex Pharmaceuticals | Suzetrigine, PregabalinEvaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | Diabetic Peripheral Neuropathic Pain | Phase 3 | Recruiting | NCT06628908 |
| May 2027 | AbbVie | LutikizumabA Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atop… | Atopic Dermatitis | Phase 2 | Active not recruiting | NCT06718101 |
| May 2027 | Acesion Pharma | AP31969Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation | Atrial Fibrillation (AF) | Phase 2 | Recruiting | NCT07267949 |
| May 2027 | Akeso | AK112, AK130A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer | Biliary Tract Cancer | Phase 1/2 | Recruiting | NCT06938321 |
| May 2027 | Biocad | anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, high doseClinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Sever… | Crohn's Disease (CD) | Phase 2 | Recruiting | NCT07078994 |
| May 2027 | Biotheus Inc. | PM8002, Chemotherapy Regimen 1, Chemotherapy Regimen 2 and 1 morePM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | CRC (Colorectal Cancer) | Phase 2 | Recruiting | NCT07133750 |
| May 2027 | Bolt Biotherapeutics, Inc. | BDC-4182A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer | Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma | Phase 1/2 | Recruiting | NCT06921837 |
| May 2027 | Boryung Pharmaceutical Co., Ltd | BR5402A, BR5402A-1, BR5402B and 5 moreA Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia | Schizophrenia | Phase 2 | Recruiting | NCT06821945 |
| May 2027 | Sino Biopharmaceutical Limited | TQB2102 for injectionA Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer | Biliary Tract Cancer | Phase 1/2 | Recruiting | NCT06431490 |
| May 2027 | Connecta Therapeutics, S.L. | CTH120Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome | Fragile X Syndrome (FXS), Fragile X Syndrome | Phase 2 | Recruiting | NCT07654114 |
| May 2027 | Disc Medicine, Inc. | DISC-0974Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Myelofibrosis; Anemia, Anemia and 5 more | Phase 1/2 | Recruiting | NCT05320198 |
| May 2027 | Draig Therapeutics Ltd | DT-101A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression | Major Depressive Disorder (MDD) | Phase 2 | Recruiting | NCT07610473 |
| May 2027 | ERX Pharmaceuticals | ERX1000A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity. | Obesity & Overweight | Phase 2 | Recruiting | NCT07570758 |
| May 2027 | Eli Lilly and Company | LY4268989, MirikizumabLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: | Ulcerative Colitis | Phase 2 | Recruiting | NCT07186101 |
| May 2027 | Eli Lilly and Company | LY3457263A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Type 2 Diabetes | Phase 2 | Recruiting | NCT06897475 |
| May 2027 | Eli Lilly and Company | LY4005130A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo | Vitiligo, Non-Segmental Vitiligo (NSV) | Phase 2 | Recruiting | NCT07533019 |
| May 2027 | Eli Lilly and Company | ClazakizumabA Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Atherosclerosis, Cardiovascular Disease and 4 more | Phase 2 | Recruiting | NCT07783802 |
| May 2027 | Eli Lilly and Company | Ramucirumab, Cyclophosphamide, Vinorelbine and 5 moreA Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | Neoplasms, Child and 1 more | Phase 2 | Recruiting | NCT05999994 |
| May 2027 | Extend Biosciences Inc. | EXT608A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism | Hypoparathyroidism | Phase 2 | Recruiting | NCT06988670 |
| May 2027 | Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 TabletA Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus | T2DM | Phase 2 | Recruiting | NCT07599410 |
| May 2027 | Fusion Pharmaceuticals | FPI-2265, OlaparibFPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Metastatic Castration-resistant Prostate Cancer | Phase 2 | Active not recruiting | NCT06909825 |
| May 2027 | Gilead Sciences | Sacituzumab Govitecan-hziyStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors | Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer and 2 more | Phase 1/2 | Active not recruiting | NCT05101096 |
| May 2027 | ImmunityBio, Inc. | Gemcitabine, N-803, M-CENKA Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcit… | Platinum-resistant Ovarian Cancer | Phase 2 | Recruiting | NCT06710288 |
| May 2027 | Immunovant, Inc. | IMVT-1402A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | Graves' Disease | Phase 2 | Recruiting | NCT07018323 |
| May 2027 | Integrative Research Laboratories AB | IRL757Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy | PARKINSON DISEASE (Disorder), Apathy and 1 more | Phase 1/2 | Recruiting | NCT07461220 |
| May 2027 | Kailera Therapeutics, Inc. | RibupatideEfficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes | Obesity | Phase 2 | Active not recruiting | NCT07458269 |
| May 2027 | Qanatpharma AG | Lumacaftor 200 MGLumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients | Heart Failure With Reduced Ejection Fraction | Phase 2 | Recruiting | NCT07695090 |
| May 2027 | Seaport Therapeutics, Inc. | SPT-300An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder,… | Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | Phase 2 | Enrolling by invitation | NCT07161700 |
| May 2027 | Shanghai Huilun Pharmaceutical Co., Ltd. | Low-dose H057+standard-of-care, High-dose H057+standard-of-careA Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerba… | Acute Exacerbations of Bronchiectasis | Phase 2 | Not yet recruiting | NCT06958861 |
| May 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, PembrolizumabA Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer | Advanced Biliary Tract Cancer | Phase 2 | Recruiting | NCT06978114 |
| May 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, Lenvatinib, Finotonlimab and 1 moreA Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D… | Advanced Hepatocellular Carcinoma | Phase 2 | Recruiting | NCT06986785 |
| May 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, Axitinib, Lenvatinib and 1 moreA Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer | Renal Cancer | Phase 2 | Recruiting | NCT06962787 |
| May 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, Pembrolizumab, BevacizumabA Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer | Cervical Cancer, Endometrial Cancer | Phase 2 | Recruiting | NCT07054567 |
| May 2027 | Sinocelltech Ltd. | SCTB35 injectionA Study of SCTB35 in Patients with Systemic Lupus Erythematosus | System Lupus Erythematosus | Phase 1/2 | Recruiting | NCT06841042 |
| May 2027 | Strand Therapeutics Inc. | STX-001, Keytruda®Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT06249048 |
| May 2027 | Jiangsu Hengrui Medicine | SHR-4375A Study of SHR-4375 in Subjects With Solid Tumors | Solid Tumors | Phase 1/2 | Recruiting | NCT06764628 |
| May 2027 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ZG005 for InjectionStudy of ZG005 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Phase 2 | Active not recruiting | NCT06927687 |
| May 2027 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ZGGS18 for Injection, ZG005 for InjectionStudy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT06938880 |
| May 2027 | TaiMed Biologics Inc. | TMB-365, TMB-380, Baseline ARTHIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study | HIV -1 Infection | Phase 2 | Active not recruiting | NCT07215468 |
| May 2027 | Tego Science, Inc. | TPX-115, Cryopreserving hyaluronic acid mediumEfficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear | Partial Thickness Rotator Cuff Tears | Phase 2 | Recruiting | NCT07219654 |
| May 2027 | Teikoku Pharma USA, Inc. | 12 cm2 - 2 Active DMTS PatchesDexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type | Agitation | Phase 2 | Recruiting | NCT06052254 |
| May 2027 | Telomir Pharmaceuticals, Inc. | Zn-TelomirOral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer and 1 more | Phase 1/2 | Not yet recruiting | NCT07581314 |
| May 2027 | TricelX Inc. | Mesenchymal Stem Cell InjectionThe Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee Osteoarthritis | Osteoarthritis | Phase 1/2 | Not yet recruiting | NCT07487766 |
| May 2027 | Vaxart | VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults P… | SARS-CoV2, COVID-19 | Phase 2 | Active not recruiting | NCT06672055 |
| May 2027 | Vicore Pharma AB | BuloxibutidA Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Active not recruiting | NCT06588686 |
| May 2027 | Voyager Therapeutics | VY7523VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease | Alzheimer's Disease (AD) | Phase 1/2 | Active not recruiting | NCT06874621 |
| May 2027 | Zura Bio Ltd | TibulizumabTibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | Systemic Sclerosis (SSc), Scleroderma | Phase 2 | Active not recruiting | NCT06843239 |
| May 1, 2027 | Aqualung Therapeutics Corp. | ALT-100 mAbStudy of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS | Acute Respiratory Distress Syndrome (ARDS) | Phase 2 | Active not recruiting | NCT05938036 |
| May 1, 2027 | Daiichi Sankyo | Quizartinib, Fludarabine, Cytarabine and 2 moreSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | Acute Myeloid Leukemia | Phase 1/2 | Active not recruiting | NCT03793478 |
| May 1, 2027 | GEN İlaç ve Sağlık Ürünleri A.Ş. | SUL-238 (1500 mg t.i.d.) film-coated tablets, SUL-238 (500 mg t.i.d.) film-coated tabletsA Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Diseas… | Parkinson's Disease (PD) | Phase 2 | Recruiting | NCT07322887 |
| May 1, 2027 | Mabwell (Shanghai) Bioscience Co., Ltd. | 9MW2821+other anticancer therapy9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors | Gynecological Malignancies | Phase 1/2 | Not yet recruiting | NCT06926998 |
| May 1, 2027 | Pfizer | PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)A Study to Learn About How a New Pneumococcal Vaccine Works in Infants | Pneumococcal Disease | Phase 2 | Active not recruiting | NCT06524414 |
| May 1, 2027 | Resolve Therapeutics | RSLV-132A Study of RSLV-132 in Females With Sjögren's Disease | Primary Sjögren Syndrome | Phase 2 | Active not recruiting | NCT06440525 |
| May 1, 2027 | Servier Bio-Innovation LLC | S095035, TNG462S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | MTAP-deleted Solid Tumors | Phase 1/2 | Active not recruiting | NCT06188702 |
| May 1, 2027 | Starlight Therapeutics Inc. | STAR-001 (LP-184) will be administered via IV infusion ove…, Spironolactone (drug)A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone… | Glioblastoma (GBM) | Phase 1/2 | Not yet recruiting | NCT07431216 |
| May 2, 2027 | NuSirt Biopharma | NS-0200 (low sildenafil), NS-0200 (higher sildenafil)A Study to Evaluate the Effect of Two Fixed-Dose Leucine, Sildenafil and Metformin Combinations on Blood Pressure in Individuals With Hypert… | Hypertension | Phase 2 | Not yet recruiting | NCT07647003 |
| May 4, 2027 | AstraZeneca | Fluorouracil (5-FU), Capecitabine, Durvalumab and 7 morePh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | Gastric Cancer | Phase 2 | Active not recruiting | NCT04379596 |
| May 4, 2027 | GSK | GSK3862995BA Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis | Bronchiectasis | Phase 2 | Recruiting | NCT07201051 |
| May 4, 2027 | Merck & Co. | pembrolizumabStudy of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Advanced Cancer, Anal Carcinoma and 23 more | Phase 2 | Active not recruiting | NCT02628067 |
| May 5, 2027 | Merck & Co. | Belzutifan, Fulvestrant, Everolimus and 1 moreStudy of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | Metastatic Breast Cancer | Phase 2 | Active not recruiting | NCT06428396 |
| May 6, 2027 | Solid Biosciences Inc. | SGT-003A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | Duchenne Muscular Dystrophy | Phase 1/2 | Recruiting | NCT06138639 |
| May 7, 2027 | Rhythm Pharmaceuticals, Inc. | Part C: RM-718, Part D: RM-718A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | Hypothalamic Obesity, Prader-Willi Syndrome and 1 more | Phase 1/2 | Active not recruiting | NCT06239116 |
| May 7, 2027 | Shanghai Mabgeek Biotech.Co.Ltd | MG-K10 InjectionA Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria | Chronic Urticaria, Idiopathic | Phase 2 | Not yet recruiting | NCT07838727 |
| May 10, 2027 | Akeso | TT-00420 (tinengotinib), AK104, AK112A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. | Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | NCT07052253 |
| May 10, 2027 | Regeneron Pharmaceuticals | Ubamatamab, Cemiplimab, Sarilumab and 1 moreStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other… | Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer and 4 more | Phase 1/2 | Recruiting | NCT03564340 |
| May 11, 2027 | AusperBio Therapeutics Inc. | AHB-137Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions | Hepatitis B, Chronic | Phase 2 | Recruiting | NCT07654283 |
| May 11, 2027 | Innovent Biologics | Compound Betamenth Group, IBI3011 GROUPA Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis | Acute Gouty Arthritis | Phase 2 | Not yet recruiting | NCT07842497 |
| May 12, 2027 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1803 injectionGR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | Phase 2 | Active not recruiting | NCT06566547 |
| May 15, 2027 | Regeneron Pharmaceuticals | ALN-CIDEBA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunct… | Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis | Phase 1/2 | Recruiting | NCT06836609 |
| May 15, 2027 | Shanghai Henlius Biotech | HLX43 DOSE 1 IN ≥2L TNBC, HLX43 DOSE 2 IN ≥2L TNBC, HLX43 DOSE 1 + HLX10 and 3 morePhase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastati… | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | Phase 2 | Not yet recruiting | NCT07487519 |
| May 15, 2027 | Zhuhai Yufan Biotechnologies Co., Ltd | PRJ1-3024A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors | Advanced Solid Tumor, Advanced Solid Malignancies | Phase 1/2 | Recruiting | NCT05315167 |
| May 16, 2027 | Novo | CDR132LA Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly … | Heart Failure | Phase 2 | Recruiting | NCT06979375 |
| May 17, 2027 | Hangzhou Sumgen Biotech Co., Ltd. | low dose group, high dose groupSG301-SC Injection Safety Study in Subjects With Primary ITP Patients | Primary Immune Thrombocytopenia | Phase 2 | Recruiting | NCT07710248 |
| May 17, 2027 | Novartis | GIA632Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | Phase 2 | Active not recruiting | NCT07220577 |
| May 17, 2027 | Sanofi | Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine and 4 moreSafety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers,… | Meningococcal Immunization, Healthy Volunteers | Phase 1/2 | Active not recruiting | NCT06647407 |
| May 17, 2027 | UCB | GalvokimigA Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With… | Atopic Dermatitis | Phase 2 | Active not recruiting | NCT07277660 |
| May 18, 2027 | Sanofi | SAR402663, DiluentA Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration | Phase 1/2 | Active not recruiting | NCT06660667 |
| May 20, 2027 | Regeneron Pharmaceuticals | Cemiplimab, Platinum-based chemotherapy, REGN7075A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable No… | Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | NCT06465329 |
| May 23, 2027 | Eveliqure Biotechnologies GmbH | ShigETEC vaccine, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFUSafety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healt… | Shigella | Phase 2 | Recruiting | NCT07049159 |
| May 25, 2027 | Almirall, S.A. | LAD191, AdalimumabA Study of LAD191 in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | Phase 2 | Recruiting | NCT07151937 |
| May 25, 2027 | ImmunityBio, Inc. | CD19 t-haNK- IV AdministrationStudy of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma | Relapsed B-Cell Non Hodgkin Lymphoma | Phase 2 | Recruiting | NCT07125872 |
| May 25, 2027 | Novartis | ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone) and 1 moreA Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | Prostate Cancer Metastatic | Phase 1/2 | Active not recruiting | NCT05067140 |
| May 26, 2027 | Bristol-Myers Squibb | BMS-986368A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | Multiple Sclerosis Spasticity | Phase 2 | Recruiting | NCT06782490 |
| May 26, 2027 | Sichuan Huiyu Pharmaceutical Co., Ltd | Test Product HY07121Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors | Safety, Tolerability and 1 more | Phase 1/2 | Recruiting | NCT06639256 |
| May 28, 2027 | Alnylam Pharmaceuticals | ALN-4324A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Recruiting | NCT07465224 |
| May 28, 2027 | AstraZeneca | AZD5305, Paclitaxel, Carboplatin and 3 moreStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | Ovarian Cancer, Breast Cancer and 11 more | Phase 1/2 | Active not recruiting | NCT04644068 |
| May 28, 2027 | Merck KGaA | Nirogacestat oral tabletA Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) | Desmoid Tumor, Aggressive Fibromatosis | Phase 2 | Active not recruiting | NCT07170644 |
| May 29, 2027 | Shanghai JMT-Bio Inc. | JSKN003, Trastuzumab, Pertuzumab and 1 moreA Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Me… | HER2-positive Recurrent or Metastatic Breast Cancer | Phase 2 | Not yet recruiting | NCT07545044 |
| May 30, 2027 | Acrivon Therapeutics, Inc. | ACR-368, Gemcitabine, OncoSignatureA Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Endometrial Adenocarcinoma | Phase 2 | Recruiting | NCT05548296 |
| May 30, 2027 | Advanced Imaging Projects, LLC | Ga-68-IACSafety and Efficacy of Ga68-IAC PET/CT for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients | Angiogenic Breast Cancer | Phase 1/2 | Not yet recruiting | NCT04480619 |
| May 30, 2027 | Hansoh Pharmaceutical Group | HS-10542Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Phase 1/2 | Recruiting | NCT07470762 |
| May 30, 2027 | Jiangsu vcare pharmaceutical technology co., LTD | VC005 tabletsA Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo | Non-Segmental Vitiligo | Phase 1/2 | Not yet recruiting | NCT07828639 |
| May 30, 2027 | Multitude Therapeutics Inc. | AMT-116, AK112AMT-116 in Combination With AK112 in Patients With Lung Cancer | Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 1/2 | Recruiting | NCT07590531 |
| May 30, 2027 | Nerviano Medical Sciences | NMS-03305293, TemozolomidePh I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Glioblastoma, Diffuse Glioma | Phase 1/2 | Active not recruiting | NCT04910022 |
| May 30, 2027 | Newish Biotech (Wuxi) Co., Ltd. | NWRD08 administered by electroporationEvaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL | High-grade Squamous Intraepithelial Lesion (HSIL) | Phase 2 | Recruiting | NCT07175662 |
| May 31, 2027 | CSPC Pharmaceutical Group | SYHX1901Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients | Severe Alopecia Areata | Phase 2 | Not yet recruiting | NCT06562894 |
| May 31, 2027 | Bristol-Myers Squibb | Elranatamab, Mezigdomide, DexamethasoneA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With … | Multiple Myeloma | Phase 1/2 | Recruiting | NCT06988488 |
| May 31, 2027 | Cognition Therapeutics Inc | CT1812A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | Early Alzheimer's Disease | Phase 2 | Active not recruiting | NCT05531656 |
| May 31, 2027 | Day One Biopharmaceuticals, Inc. | TovorafenibA Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tu… | Low-grade Glioma, Advanced Solid Tumor | Phase 2 | Recruiting | NCT04775485 |
| May 31, 2027 | Exegi Pharma, LLC | EXE-346Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF) | Ileal Pouch | Phase 1/2 | Recruiting | NCT05938465 |
| May 31, 2027 | Far East Bio-Tec Co., Ltd | Apomivir®Study to Investigate the Efficacy and Safety of Apomivir® | Influenza | Phase 2 | Not yet recruiting | NCT01677689 |
| May 31, 2027 | GSK | Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1 and 4 moreA Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in F… | Urinary Tract Infections | Phase 1/2 | Recruiting | NCT06702449 |
| May 31, 2027 | GSK | Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, BepirovirsenA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis … | Chronic Hepatitis B Virus Infection, Hepatitis B | Phase 2 | Active not recruiting | NCT06537414 |
| May 31, 2027 | Johnson & Johnson | Amivantamab IV, Amivantamab SC, Lazertinib and 11 moreEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NS… | Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | NCT06120140 |
| May 31, 2027 | Merck & Co. | Coformulated favezelimab/pembrolizumab, Coformulated vibostolimab/pembrolizumab, EV and 1 moreA Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial … | Metastatic Urothelial Carcinoma, Urothelial Neoplasms | Phase 1/2 | Active not recruiting | NCT05845814 |
| May 31, 2027 | Nanjing Chia-tai Tianqing Pharmaceutical | NTB003An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) | Thyroid Eye Disease | Phase 1/2 | Not yet recruiting | NCT07462130 |
| May 31, 2027 | Oneness Biotech Co., Ltd. | FB825Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | Phase 2 | Recruiting | NCT06397911 |
| May 31, 2027 | Photozig, Inc. | Recharge Behavioral Therapy, Traditional Educational/Resources ProgramCaring Recharge Project for Caregivers of Individuals With Alzheimer's Disease | Caregiver Stress | Phase 2 | Recruiting | NCT07764185 |
| May 31, 2027 | Revolution Medicines, Inc. | RMC-6236Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and 2 more | Phase 1/2 | Recruiting | NCT05379985 |
| May 31, 2027 | Ribocure Pharmaceuticals AB | RBD5044Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia | Dyslipidemias | Phase 2 | Recruiting | NCT06797401 |
| May 31, 2027 | Jiangsu Hengrui Medicine | SHR-A2102, Adebrelimab injection, SHR-8068 injectionA Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Phase 1/2 | Recruiting | NCT06639347 |
| May 31, 2027 | Shenzhen Wingor Biotechnology Co., Ltd. | hUC-MSCs treatment (high dose), hUC-MSCs treatment (low dose)A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS | Acute Ischemic Stroke AIS | Phase 2 | Recruiting | NCT07084012 |
| May 31, 2027 | Starton Holdings, Inc. | Lenalidomide, Lenalidomide 25 MG Oral CapsuleSafety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) | Multiple Myeloma | Phase 1/2 | Recruiting | NCT06087653 |
| May 31, 2027 | ZetrOZ, Inc. | Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, Intra articular injectionLong Duration High Frequency Ultrasound for the Treatment of Osteoarthritis | Arthritis, Osteo Arthritis of the Knee | Phase 2 | Not yet recruiting | NCT07515872 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.